LENZ — LENZ Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1815776 ·
Last close
$3.50
Market Cap
$109.97M
52W High
$32.13
52W Low
$2.80
ADV30
1,075,558
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 5,486,000 | 5,206,000 | -34,172,000 | -31,918,000 | 236,596,000 | 24,208,000 | 17,334,000 |
| Mar 2026 | 1,901,000 | 825,000 | -44,135,000 | -41,488,000 | 272,535,000 | 24,772,000 | 26,043,000 |
| Dec 2025 | 1,588,000 | — | -38,463,000 | -35,896,000 | 305,876,000 | 25,179,000 | 21,537,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-127,631,000
Investing CF
$9,761,000
Financing CF
$123,024,000
CapEx
$-511,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.49
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-331,516,000
Inventory
$4,760,000
Receivables
$913,000
ST Investments
$166,750,000
EBIT TTM
$-149,688,000
Pretax Income TTM
$-140,266,000
Interest Exp TTM
—
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$12,359,000
EBITDA
$-149,251,008
Free Cash Flow
$-79,889,000
Enterprise Value
$-86,870,960
Total Cash
$197,303,008
Total Debt
$460,000
Shares Out
31,420,583
Trailing EPS
$-4.53
Book Value
$6.11
ROE
-72.7%
ROA
-44.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 19,088,000 | -91,138,000 | -82,127,000 | 305,876,000 | 21,537,000 | 284,339,000 | -69,170,000 |
| Dec 2024 | 0 | -58,610,000 | -49,769,000 | 215,304,000 | 11,220,000 | 204,084,000 | -59,391,000 |
| Dec 2023 | 0 | -72,429,000 | -69,968,000 | 70,376,000 | 163,088,000 | -92,712,000 | -60,380,000 |
| Dec 2022 | 15,000,000 | -10,483,000 | -10,811,000 | 46,951,000 | 71,120,000 | -24,169,000 | -4,091,000 |
TTM Snapshot
Revenues TTM
$19,152,000
NetIncome TTM
$-126,002,000
OpCashFlow TTM
—
Assets (Latest)
$236,596,000
Forward EPS
$-1.47
Max Pain — expiry 2027-03-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $3.21 · call volume: 4 · put volume: 346
Expected Move to 2027-03-19:
±$2.08
(64.80%) —
implied range
$1.13 –
$5.29
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MOLN | MOLECULAR PARTNERS AG | $109.55M | $2.86 | — |
| CMPX | Compass Therapeutics, Inc. | $109.26M | $0.61 | — |
| CRDL | Cardiol Therapeutics Inc. | $113.53M | $0.97 | — |
| ENGN | enGene Therapeutics Inc. | $115.27M | $1.72 | — |
| ZURA | Zura Bio Ltd | $99.70M | $1.03 | — |
News headlines (Yahoo Finance, 1h cache)
LENZ Therapeutics (LENZ) Stock Fair Value Moves Lower As Analysts Split On VIZZ
2026-11-04 07:10 · Yahoo
LENZ (LENZ) Q3 2026 Earnings Call Transcript
2026-11-02 19:17 · Yahoo
LENZ Therapeutics (LENZ) Stock Rallies As Q3 Results Expose Cash Burn
2026-10-30 10:11 · Yahoo
LENZ Therapeutics Q3 Earnings Call Highlights
2026-10-29 19:14 · Yahoo
LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Misses Revenue Estimates
2026-10-28 20:45 · Yahoo
LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession
2026-10-28 20:30 · Yahoo
LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
2026-10-22 12:00 · Yahoo
LENZ Therapeutics (LENZ) Stock Fair Value Falls After Analysts Cut VIZZ Launch Expectations
2026-10-21 04:27 · Yahoo
LENZ Therapeutics (LENZ) Stock Sees Fair Value Moves Lower After Analyst Target Cuts
2026-08-15 01:12 · Yahoo
LENZ Therapeutics Inc (LENZ) (Q2 2026) Earnings Call Highlights: VIZZ Launch Momentum ...
2026-08-12 05:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.